Phase II, 2nd Line Melanoma - RAND Monotherapy
NCT00612664
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
158
Enrollment
INDUSTRY
Sponsor class
Conditions
Melanoma
Interventions
DRUG:
Anti-CD137 (4-1BB) (BMS-663513)
Sponsor
Bristol-Myers Squibb